GENBGenerate Biomedicines, Inc.vs its industry peers
A metric-by-metric comparison of Generate Biomedicines, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GENBEsta | $2.3B#8 | — | 5.0x#9 | — | — | — | — | 0.0%#3 | — | — | — | — |
| SUPN | $2.5B#1 | — | 2.4x#3 | 3.5x#5 | 8.6%#6 | -152.2%#14 | -8.7%#4 | -3.7%#4 | -5.0%#4 | — | -3.9%#13 | — |
| VRDN | $2.5B#2 | — | 3.8x#6 | 35.3x#7 | 23359.9%#1 | -26.9%#7 | -512.9%#9 | -51.7%#12 | -54.5%#6 | — | 18.6%#11 | — |
| VERA | $2.5B#3 | — | 6.1x#10 | — | — | -96.9%#11 | — | -73.5%#13 | -72.7%#7 | — | 40.3%#7 | — |
| HRMY | $2.5B#4 | 13.8x#2 | 2.5x#4 | 2.9x#4 | 21.5%#5 | 9.1%#5 | 24.0%#2 | 15.9%#1 | 25.5%#1 | 4#1 | 32.7%#9 | — |
| SLS | $2.3B#5 | — | 17.0x#15 | — | -100.0%#12 | 13.0%#3 | — | -19.5%#8 | — | — | 583.8%#1 | — |
| NKTR | $2.3B#6 | — | 2.6x#5 | 42.0x#8 | -43.9%#11 | -37.8%#9 | -253.7%#7 | -18.2%#6 | -14.0%#5 | — | 32.9%#8 | — |
| OCUL | $2.3B#7 | — | 4.4x#7 | 44.4x#9 | -18.5%#10 | -37.4%#8 | -519.8%#10 | -51.1%#11 | — | — | -13.5%#14 | — |
| PVLA | $2.2B#9 | — | 10.3x#14 | 52.4x#10 | 65.3%#4 | -139.3%#12 | -90.2%#6 | -19.2%#7 | — | — | 175.5%#2 | — |
| PBH | $2.2B#11 | 13.0x#1 | 1.1x#1 | 2.0x#3 | -4.3%#9 | -11.3%#6 | 28.4%#1 | 9.9%#2 | 5.9%#2 | 4#1 | -27.3%#15 | — |
| TRVI | $2.2B#10 | — | 6.9x#11 | — | — | 10.7%#4 | — | -13.3%#5 | — | — | 94.2%#3 | — |
| SRPT | $2.2B#12 | — | 1.4x#2 | 1.2x#2 | 4.3%#8 | -403.3%#15 | -37.5%#5 | -46.7%#10 | -73.0%#8 | — | 21.6%#10 | — |
| ZBIO | $2.2B#13 | — | 8.8x#13 | 216.7x#11 | 100.0%#3 | -140.6%#13 | -3830.6%#11 | -152.9%#15 | -296.6%#10 | — | 74.0%#5 | — |
| BHC | $2.1B#14 | — | — | 0.2x#1 | 6.7%#7 | 441.3%#1 | 17.7%#3 | — | 3.6%#3 | — | -1.9%#12 | 16.6%#1 |
| NUVB | $2.1B#15 | — | 8.4x#12 | 33.8x#6 | 699.0%#2 | 64.0%#2 | -338.7%#8 | -80.6%#14 | -87.4%#9 | — | 84.8%#4 | — |
| RAPP | $2.0B#16 | — | 4.8x#8 | — | — | -42.4%#10 | — | -26.4%#9 | — | — | 62.2%#6 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice